Therapeutic Horizons of CRISPR/Cas9 Genome Editing in Overcoming Bacterial Antimicrobial Resistance: A Comprehensive Narrative Review

1. Introduction

Antimicrobial resistance (AMR) is a rapidly accelerating global health crisis that threatens to undermine modern medical interventions [1,2]. The widespread dissemination of multidrug-resistant (MDR), extensively drug-resistant (XDR), and pandrug-resistant (PDR) bacterial strains has severely limited clinical treatment options [1,3]. Broad-spectrum antibiotics, while historically effective, suffer from two major drawbacks: they accelerate the evolutionary selection pressure driving resistance, and they disrupt the host’s protective commensal microbiome [3,4]. Consequently, there is an urgent imperative to develop sequence-specific, targeted antimicrobial therapeutics capable of selectively neutralizing pathogens without disturbing beneficial microflora [4,5].

Among prospective next-generation biotechnologies, the clustered regularly interspaced short palindromic repeats-associated protein 9 (CRISPR/Cas9) genome-editing framework stands out for its high specificity and modular adaptiveness [1,5]. Originally discovered as a prokaryotic adaptive immune mechanism against mobile genetic elements (MGEs) and bacteriophages, CRISPR/Cas9 has been repurposed into an exceptionally versatile genome-engineering toolkit [6,7]. When deployed against bacterial pathogens, CRISPR/Cas9 can be engineered to target specific antibiotic resistance genes (ARGs) or essential chromosomal loci [1,7]. By inducing double-strand DNA breaks (DSBs) or targeted transcriptional repressions, CRISPR platforms can re-sensitize resistant bacteria to conventional antibiotics, cure resistance plasmids, or directly induce lethal auto-cleavage of the bacterial genome [1,8].

Despite its vast potential, transitioning CRISPR/Cas9 from proof-of-concept laboratory studies to real-world clinical applications requires overcoming substantial hurdles [5,8]. Key translational challenges include achieving efficient sequence delivery across dense bacterial walls, suppressing host immune responses, navigating anti-CRISPR (Acr) bacterial counter-defenses, and evaluating long-term ecological impacts [5,8,9]. This narrative review provides a detailed examination of the operational mechanics, target genetic pathways, comparative delivery modalities, safety considerations, and future prospects of CRISPR/Cas9 technology as a weapon against antimicrobial resistance.

2. Structural and Operational Mechanics of CRISPR/Cas9 Systems

2.1. The Native Prokaryotic Adaptive Immune Pathway

In prokaryotic organisms, the CRISPR/Cas framework functions as an adaptive immune system that safeguards archaeal and bacterial hosts against foreign genetic invasion, such as phages and conjugative plasmids [6,10]. This defensive response occurs across three coordinated phases: Adaptation, Expression, and Interference [6,11].

• Adaptation (Spacer Acquisition): Upon invasion by a foreign nucleic acid, the Cas1–Cas2 endonuclease complex recognizes the target DNA, excises a short conserved segment known as a protospacer, and integrates it into the host’s genomic CRISPR array as a novel “spacer” [6,9,12]. This integration creates a temporal, heritable genetic memory of past infections [6,13].
• Expression (crRNA Biogenesis): When re-exposed to a previously encountered pathogen, the genomic CRISPR array is transcribed into a long precursor CRISPR RNA (pre-crRNA) transcript [11,12]. Concurrently, a small non-coding trans-activating crRNA (tracrRNA) is transcribed nearby [11,13]. The tracrRNA hybridizes with the repeat regions of the pre-crRNA, forming a double-stranded RNA complex that is processed by endogenous RNase III and Cas proteins into mature crRNA units [11,13].
• Interference: Each mature crRNA–tracrRNA duplex forms a ribonucleoprotein (RNP) complex with the Cas9 endonuclease [11,13]. The complex searches for invasive DNA containing a target sequence complementary to the 20-nucleotide spacer region of the crRNA, positioned adjacent to a short conserved sequence known as the Protospacer Adjacent Motif (PAM; e.g., 5′-NGG-3′ for Streptococcus pyogenes Cas9) [1,12]. Upon PAM recognition and DNA strand invasion, the two catalytic domains of Cas9—HNH and RuvC—cleave the complementary and non-complementary target strands, respectively, generating a double-strand break (DSB) that degrades the foreign DNA [1,8,12].

Figure 1. Sequential stages of the native prokaryotic Type II CRISPR/Cas9 adaptive immune mechanism. Prokaryotic Type II CRISPR-Cas9 adaptive immune mechanism. Source: Trinset / Getty Images.

Figure 1. Sequential stages of the native prokaryotic Type II CRISPR/Cas9 adaptive immune mechanism. Prokaryotic Type II CRISPR-Cas9 adaptive immune mechanism. Source: Trinset / Getty Images.

2.2. Re-Engineered Synthetic CRISPR/Cas9 Systems

To simplify molecular cloning and experimental applications, Jinek and colleagues synthetically fused the dual-RNA structure (crRNA and tracrRNA) into a single continuous transcript called a single-guide RNA (sgRNA) [1,8]. The 5′ terminus of the sgRNA contains a customizable 20-nucleotide sequence that dictates target specificity, while the remaining 3′ scaffold region binds to the Cas9 protein [1,14]. This two-component setup (sgRNA + Cas9) allows scientists to target almost any genomic or extrachromosomal sequence containing a matching PAM site [1,15].

Figure 2. Structural schematic of an engineered Single-Guide RNA (sgRNA).

Figure 2. Structural schematic of an engineered Single-Guide RNA (sgRNA).

Following Cas9-induced double-strand cleavage, the target cell attempts to repair the damaged DNA [28,29]. In prokaryotes and eukaryotes, these repairs proceed through two primary pathways:

• Non-Homologous End Joining (NHEJ): An error-prone process that directly re-ligates broken DNA ends without requiring a repair template [28]. This pathway frequently introduces insertions or deletions (indels) that cause frameshift mutations, disrupting the target gene’s coding sequence [28,29]. While ubiquitous in eukaryotic cells, classical NHEJ machinery is absent or inefficient in most bacterial species [28].
• Homology-Directed Repair (HDR): A high-fidelity repair mechanism that requires an exogenous or endogenous homologous DNA template to guide repair [28,29]. In the presence of a engineered donor DNA construct, HDR can introduce precise sequence alterations, substitute specific bases, or insert novel functional genes [28,29].

2.3. Engineered Cas9 Derivatives: dCas9 and nCas9

Beyond simple DNA cleavage, molecular engineering has expanded the CRISPR toolkit by introducing mutations into the catalytic domains of Cas9 [1,16]:

• Deactivated Cas9 (dCas9): Point mutations in both the HNH (H840A) and RuvC (D10A) catalytic domains eliminate nuclease cleavage activity while retaining sequence-specific DNA-binding capability [16,22]. When targeted to a promoter or coding region, dCas9 physically blocks transcription elongation—a strategy known as CRISPR interference (CRISPRi) [16,26]. Fusing dCas9 to transcriptional activator domains (CRISPRa) or epigenetic modifiers enables precise regulation of gene expression without introducing permanent DNA breaks [16,22,25].
• Cas9 Nickase (nCas9): Inactivating a single catalytic domain (either HNH or RuvC) yields a nickase variant capable of creating single-stranded nicks rather than double-stranded breaks [1,16]. Paired nicking strategies using dual nCas9-sgRNA complexes can dramatically reduce off-target cleavage events while preserving high editing efficiency [1,16].

Figure 3. Functional comparisons of Wild-Type Cas9, Deactivated dCas9, and Cas9 Nickase variants.

Figure 3. Functional comparisons of Wild-Type Cas9, Deactivated dCas9, and Cas9 Nickase variants.

3. Mechanisms of CRISPR/Cas9 Action Against Antimicrobial Resistance

CRISPR/Cas9 platforms offer versatile strategies to eliminate resistance mechanisms, re-sensitize pathogens, and suppress gene transfer [1,30,31].

Figure 4. Primary modalities for targeting bacterial resistance with CRISPR/Cas9.

Figure 4. Primary modalities for targeting bacterial resistance with CRISPR/Cas9.

3.1. Direct Chromosomal Cleavage and Bacterial Autolysis

Unlike eukaryotic organisms, most bacteria lack robust non-homologous end joining (NHEJ) repair systems [28,30]. Consequently, when Cas9 generates a double-strand break (DSB) within a chromosomal locus, the bacterial cell cannot easily repair the damaged DNA [30,32]. Chromosomal cleavage triggers rapid genomic degradation by endogenous exonucleases, causing cell death [30,32]. Targeting essential survival genes or chromosomally integrated antibiotic resistance genes thus functions as a sequence-specific bactericidal agent [32,33].

3.2. Plasmid Curing and Re-Sensitization

Many clinically relevant resistance determinants—such as extended-spectrum $\beta$-lactamases (ESBLs), carbapenemases, and colistin resistance markers—are encoded on multi-copy extrachromosomal plasmids [30,34,35]. Programming CRISPR/Cas9 to target plasmid-specific sequences induces plasmid linearization and subsequent degradation by host nucleases, a process called “plasmid curing” [34,35]. Curing these resistance vectors strips the host bacteria of their defense mechanisms, restoring sensitivity to conventional antibiotic therapies without harming the host cell [34,35,36].

3.3. Interruption of Horizontal Gene Transfer (HGT)

Horizontal gene transfer (HGT) via conjugation, transformation, and transduction drives the rapid global spread of multidrug resistance across diverse bacterial populations [30,34]. By targeting shared plasmid backbones, transposons, or insertion sequences involved in conjugation, CRISPR/Cas9 platforms can cleave these mobile elements during transfer [34,37]. This intervention blocks the dissemination of resistance factors across both pathogenic strains and commensal microflora [34,37].

3.4. Biofilm Disruption and Virulence Attenuation

Bacterial biofilms present a major clinical obstacle, creating protective matrices that reduce antibiotic penetration and shield pathogens from host immune responses [30,38]. CRISPR/Cas9 and dCas9 (CRISPRi) platforms can be targeted to key genes involved in biofilm matrix synthesis, quorum sensing, and virulence factor expression [30,38]. Suppressing these pathways disrupts biofilm structure, renders bacteria planktonic, and restores susceptibility to both host immune defenses and standard antibiotic treatments [30,38].

4. Targeted Resistance Genes Across Major Pathogens

CRISPR/Cas9 technology has been deployed against a wide array of resistance targets in both Gram-positive and Gram-negative pathogens [1,30,39].

Table 1. Summary of CRISPR/Cas9 targets, host pathogens, and therapeutic outcomes across clinical AMR strains.

Host Pathogen	Targeted Resistance Determinants	Resistance Mechanism	Phenotypic and Clinical Impact	Primary References
Staphylococcus aureus (MRSA)	mecA, aacA-aphD, grlA, grlB	Penicillin-binding protein 2a (PBP2a), aminoglycoside modification, fluoroquinolone mutations	Restores sensitivity to $\beta$-lactams, aminoglycosides, and fluoroquinolones; induces strain-specific autolysis.	[18,39,40,41]
Enterococcus faecalis / E. faecium (VRE)	vanA, vanB gene clusters	Cell wall peptidoglycan precursor modification	Cures vancomycin resistance plasmids; eliminates VRE colonisation in intestinal models.	[42,48,49]
Streptococcus pneumoniae	erm(B), mef(A/E), mutated pbp2b/2x	Ribosomal methylation, efflux pumps, altered penicillin-binding proteins	Reverses macrolide and $\beta$-lactam resistance; reduces systemic colonization.	[43,50]
Escherichia coli	blaCTX-M, blaSHV, blaTEM, mcr-1 to mcr-10	Extended-spectrum $\beta$-lactamases, phosphoethanolamine transferase	Neutralizes ESBL activity; reverses colistin resistance; cures conjugative resistance plasmids.	[7,51,52]
Klebsiella pneumoniae	blaKPC, blaNDM, blaOXA-48, blaVIM	Carbapenem hydrolyzing $\beta$-lactamase enzymes	Cleaves carbapenemase plasmids; re-sensitizes MDR strains to carbapenems in vitro and in vivo.	[3,4,35,53]
Pseudomonas aeruginosa	blaVIM, blaIMP, mexAB-oprM, mexCD-oprJ	Metalloproteinases, multidrug efflux pump systems	Suppresses efflux pump activity; increases intracellular drug retention; restores carbapenem sensitivity.	[1,31,54]
Acinetobacter baumannii	blaOXA-23, blaOXA-24, adeABC cluster	Class D carbapenemases, resistance-nodulation-division (RND) efflux	Reverses carbapenem resistance; lowers minimum inhibitory concentrations (MICs) across clinical isolates.	[30,32,55]
Mycobacterium tuberculosis	katG, rpoB, gyrA, rrs, eis loci	Mutations altering catalase-peroxidase, RNA polymerase, DNA gyrase, and rRNA	Restores sensitivity to isoniazid, rifampicin, fluoroquinolones, and aminoglycosides.	[1,40,56]

Table 1. Summary of CRISPR/Cas9 targets, host pathogens, and therapeutic outcomes across clinical AMR strains.

Host Pathogen	Targeted Resistance Determinants	Resistance Mechanism	Phenotypic and Clinical Impact	Primary References
Staphylococcus aureus (MRSA)	mecA, aacA-aphD, grlA, grlB	Penicillin-binding protein 2a (PBP2a), aminoglycoside modification, fluoroquinolone mutations	Restores sensitivity to $\beta$-lactams, aminoglycosides, and fluoroquinolones; induces strain-specific autolysis.	[18,39,40,41]
Enterococcus faecalis / E. faecium (VRE)	vanA, vanB gene clusters	Cell wall peptidoglycan precursor modification	Cures vancomycin resistance plasmids; eliminates VRE colonisation in intestinal models.	[42,48,49]
Streptococcus pneumoniae	erm(B), mef(A/E), mutated pbp2b/2x	Ribosomal methylation, efflux pumps, altered penicillin-binding proteins	Reverses macrolide and $\beta$-lactam resistance; reduces systemic colonization.	[43,50]
Escherichia coli	blaCTX-M, blaSHV, blaTEM, mcr-1 to mcr-10	Extended-spectrum $\beta$-lactamases, phosphoethanolamine transferase	Neutralizes ESBL activity; reverses colistin resistance; cures conjugative resistance plasmids.	[7,51,52]
Klebsiella pneumoniae	blaKPC, blaNDM, blaOXA-48, blaVIM	Carbapenem hydrolyzing $\beta$-lactamase enzymes	Cleaves carbapenemase plasmids; re-sensitizes MDR strains to carbapenems in vitro and in vivo.	[3,4,35,53]
Pseudomonas aeruginosa	blaVIM, blaIMP, mexAB-oprM, mexCD-oprJ	Metalloproteinases, multidrug efflux pump systems	Suppresses efflux pump activity; increases intracellular drug retention; restores carbapenem sensitivity.	[1,31,54]
Acinetobacter baumannii	blaOXA-23, blaOXA-24, adeABC cluster	Class D carbapenemases, resistance-nodulation-division (RND) efflux	Reverses carbapenem resistance; lowers minimum inhibitory concentrations (MICs) across clinical isolates.	[30,32,55]
Mycobacterium tuberculosis	katG, rpoB, gyrA, rrs, eis loci	Mutations altering catalase-peroxidase, RNA polymerase, DNA gyrase, and rRNA	Restores sensitivity to isoniazid, rifampicin, fluoroquinolones, and aminoglycosides.	[1,40,56]

5. Delivery Systems for Bacterial CRISPR/Cas9 Therapeutics

The clinical application of CRISPR/Cas9 as an antimicrobial relies heavily on the development of safe and efficient delivery vehicles capable of introducing the Cas9 protein and guide RNA into target bacterial cells [1,36,46].

Figure 5. Overview of primary delivery modalities for bacterial CRISPR systems(103).

Figure 5. Overview of primary delivery modalities for bacterial CRISPR systems(103).

5.1. Bacteriophage-Mediated Vector Delivery (Phagemids)

Engineered bacteriophages (phagemids) represent one of the most effective methods for delivering CRISPR components into target bacteria [36,42]. Phagemids combine phage capsids with plasmid vectors containing CRISPR sequences [36,72].

• Mechanistic Advantages: Phages naturally recognize specific surface receptors on host bacteria, facilitating high-efficiency injection of packaged CRISPR constructs [36,73].
• Key Limitations: Phage host ranges are often narrow, meaning a specific phage vector may not infect all clinical isolates of a given pathogen species [36,79]. Furthermore, host immune clearance and the rapid emergence of phage-resistant bacterial mutants present ongoing hurdles [36,79].

5.2. Conjugative Plasmid Transfer Systems

Conjugative plasmids leverage natural bacterial conjugation machinery to spread CRISPR constructs through dense bacterial communities, such as those found in gut microbiota or bio-films [74,88].

• Mechanistic Advantages: Conjugative systems can transfer genetic payloads across diverse bacterial species without relying on specific phage receptors [74,88].
• Key Limitations: Conjugation efficiency can vary widely depending on environmental conditions and cell density [74,88]. There is also a risk that conjugative plasmids may transfer non-target resistance factors or persist unexpectedly within commensal populations [74,88].

5.3. Nanoparticle and Non-Viral Delivery Systems

Synthetic nanocarriers—including lipid nanoparticles (LNPs), polymeric nanoparticles, and gold nanoparticles—offer a non-viral strategy for delivering CRISPR RNPs or plasmids [4,75,80].

• Mechanistic Advantages: Nanoparticles shield nucleic acid and protein payloads from enzymatic degradation, reduce host immunogenicity, and can penetrate protective biofilm matrices [4,75,83].
• Key Limitations: Encapsulating macromolecular Cas9 complexes can be technically challenging, and manufacturing costs remain high [75,80]. Ensuring targeted delivery to specific bacterial pathogens without non-specific cellular uptake remains a key area of development [75,80].

5.4. Engineered Probiotic Living Therapeutics

Synthetic biology allows for the engineering of harmless commensal bacteria (e.g., Escherichia coli Nissle 1917, Lactobacillus spp.) to serve as live therapeutic delivery vehicles [76,81].

• Mechanistic Advantages: Engineered probiotics can colonize host niches, such as the gastrointestinal tract, and continuously produce and transfer CRISPR-encoding plasmids to target pathogens via conjugation [76,81].
• Key Limitations: Deploying genetically modified organisms (GMOs) raises biosafety concerns regarding uncontained dissemination, requiring built-in biocontainment measures such as synthetic kill switches [76,81].

Table 2. Comparative assessment of primary CRISPR delivery modalities in bacterial applications.

Delivery Category	Core Mechanisms of Entry	Primary Advantages	Critical Limitations	Current Level of Validation	Primary References
Bacteriophage Vectors (Phagemids)	Receptor-mediated viral DNA injection	High cell-entry efficiency; strong strain selectivity; natural infection pathways	Narrow host range; potential neutralizing immune response; risk of lysogenic integration	Advanced in vivo animal models	[36,42,72,79]
Conjugative Plasmids	Direct cell-to-cell mating bridge transfer	Capable of spreading through dense bacterial communities in situ	Variable conjugation rates; risk of off-target transfer to commensals	Preclinical in vivo gut models	[74,88]
Synthetic Nanoparticles (LNPs/Polymers)	Membrane fusion, endocytosis, or physical pore penetration	Protects payload from degradation; low immunogenicity; biofilm penetration	High production costs; potential carrier toxicity; challenges in targeted selectivity	Preclinical in vitro and animal models	[4,75,80,83]
Engineered Probiotics	Continuous in situ production and conjugative transfer	Long-term colonization; localized release within target host niches	Biocontainment risks; complex regulatory approval path for live GMOs	In vitro and preliminary in vivo models	[76,81]

Table 2. Comparative assessment of primary CRISPR delivery modalities in bacterial applications.

Delivery Category	Core Mechanisms of Entry	Primary Advantages	Critical Limitations	Current Level of Validation	Primary References
Bacteriophage Vectors (Phagemids)	Receptor-mediated viral DNA injection	High cell-entry efficiency; strong strain selectivity; natural infection pathways	Narrow host range; potential neutralizing immune response; risk of lysogenic integration	Advanced in vivo animal models	[36,42,72,79]
Conjugative Plasmids	Direct cell-to-cell mating bridge transfer	Capable of spreading through dense bacterial communities in situ	Variable conjugation rates; risk of off-target transfer to commensals	Preclinical in vivo gut models	[74,88]
Synthetic Nanoparticles (LNPs/Polymers)	Membrane fusion, endocytosis, or physical pore penetration	Protects payload from degradation; low immunogenicity; biofilm penetration	High production costs; potential carrier toxicity; challenges in targeted selectivity	Preclinical in vitro and animal models	[4,75,80,83]
Engineered Probiotics	Continuous in situ production and conjugative transfer	Long-term colonization; localized release within target host niches	Biocontainment risks; complex regulatory approval path for live GMOs	In vitro and preliminary in vivo models	[76,81]

6. Biological, Ecological, and Translational Risks

While CRISPR/Cas9 therapeutics offer significant promise, several biological, ecological, and translational challenges must be addressed prior to clinical implementation [5,87,89].

Figure 6. Major risk categories associated with clinical and environmental deployment of CRISPR antimicrobials.

Figure 6. Major risk categories associated with clinical and environmental deployment of CRISPR antimicrobials.

6.1. Off-Target Effects and Genomic Instability

Although CRISPR/Cas9 is highly sequence-specific, non-specific binding and cleavage can occur at genomic sites displaying sequence similarity to the target sgRNA [62,65,69]. Off-target cleavage in host bacterial genomes can lead to unintended mutations, rearrangements, or altered phenotypic behaviors [65,66]. When applied in human or animal host tissues, off-target editing of host eukaryotic DNA must be strictly avoided [69,70]. Implementing high-fidelity Cas9 variants (e.g., SpCas9-HF1, eSpCas9) and carefully designing sgRNAs using computational algorithms can reduce off-target cleavage events [66,99].

6.2. Bacterial Resistance to CRISPR and Anti-CRISPR (Acr) Proteins

Bacteria possess diverse evolutionary mechanisms to resist CRISPR-mediated targeting [53,86]. Single point mutations within the protospacer or adjacent PAM region can abolish sgRNA binding, enabling escape mutants to rapidly emerge under selection pressure [53,97]. Additionally, many bacteriophages and mobile genetic elements encode anti-CRISPR (Acr) proteins [53,86]. These small proteins physically bind to Cas9 or block sgRNA association, completely neutralizing cleavage activity [53,86]. Overcoming Acr-mediated inhibition and managing escape mutations are critical considerations for durable therapy design [53,86].

6.3. Ecological Impacts and Off-Target Microbiome Disruption

Deploying CRISPR antimicrobials in vivo carries potential risks for native commensal microbial communities [58,63,87]. If delivery vectors transfer CRISPR constructs to non-target beneficial bacteria, off-target genomic cleavage or plasmid curing could alter microbiome composition, potentially causing dysbiosis [58,63,97]. Furthermore, releasing engineered gene drive systems or live GMOs into natural environments raises concerns regarding unpredictable gene transfer and long-term ecosystem disruption [59,63,101].

6.4. Regulatory, Manufacturing, and Ethical Frameworks

The clinical translation of CRISPR-based therapeutics faces complex regulatory and manufacturing hurdles [58,67,68]. Classifying these therapies—whether as biological drugs, gene therapies, or live biotherapeutic products—requires establishing standardized frameworks for clinical evaluation, safety testing, and quality control [67,68,71]. Mass production of high-purity phagemids or nanoparticles under Good Manufacturing Practice (GMP) standards remains a key technical challenge [46,70]. In addition, public perception and regulatory oversight surrounding genetically modified organisms (GMOs) require robust biosafety containment strategies to prevent unintended environmental release [58,67,68].

Table 3. Risk factors, underlying mechanisms, and potential mitigation strategies for CRISPR/Cas9 therapeutic translation.

Identified Risk Domain	Primary Underlying Mechanism	Clinical & Ecological Implications	Proposed Mitigation Strategies	Primary References
Off-Target Cleavage	Mismatched binding of sgRNA to unintended genomic loci	Unintended mutations; cell toxicity; unpredictable genetic alterations	Use high-fidelity Cas9 variants (SpCas9-HF1); optimize sgRNA design using AI modeling	[65,66,69,99]
Bacterial Escape Mutants	Point mutations in target protospacer or PAM site	Re-emergence of resistant bacterial sub-populations under selection	Deploy multiplexed sgRNAs targeting multiple conserved genes simultaneously	[53,97,100]
Anti-CRISPR (Acr) Inhibition	Phage-encoded Acr proteins bind Cas9 and block nuclease function	Loss of CRISPR therapeutic activity in Acr-expressing strains	Engineer Cas9 variants that evade Acr binding; combine CRISPR with non-Cas adjuvants	[53,86]
Microbiome Dysbiosis	Unintended delivery and cleavage in beneficial commensal strains	Disruption of gut microflora; secondary infections (e.g., Clostridioides difficile)	Use narrow-spectrum phage vectors; implement strain-specific promoters	[58,63,87,97]
Environmental GMO Escape	Uncontrolled transfer of engineered delivery vectors to wild strains	Unpredictable ecological shifts; spread of modified genetic constructs	Implement synthetic kill switches; utilize non-replicative phagemids	[58,63,68,81]

Table 3. Risk factors, underlying mechanisms, and potential mitigation strategies for CRISPR/Cas9 therapeutic translation.

Identified Risk Domain	Primary Underlying Mechanism	Clinical & Ecological Implications	Proposed Mitigation Strategies	Primary References
Off-Target Cleavage	Mismatched binding of sgRNA to unintended genomic loci	Unintended mutations; cell toxicity; unpredictable genetic alterations	Use high-fidelity Cas9 variants (SpCas9-HF1); optimize sgRNA design using AI modeling	[65,66,69,99]
Bacterial Escape Mutants	Point mutations in target protospacer or PAM site	Re-emergence of resistant bacterial sub-populations under selection	Deploy multiplexed sgRNAs targeting multiple conserved genes simultaneously	[53,97,100]
Anti-CRISPR (Acr) Inhibition	Phage-encoded Acr proteins bind Cas9 and block nuclease function	Loss of CRISPR therapeutic activity in Acr-expressing strains	Engineer Cas9 variants that evade Acr binding; combine CRISPR with non-Cas adjuvants	[53,86]
Microbiome Dysbiosis	Unintended delivery and cleavage in beneficial commensal strains	Disruption of gut microflora; secondary infections (e.g., Clostridioides difficile)	Use narrow-spectrum phage vectors; implement strain-specific promoters	[58,63,87,97]
Environmental GMO Escape	Uncontrolled transfer of engineered delivery vectors to wild strains	Unpredictable ecological shifts; spread of modified genetic constructs	Implement synthetic kill switches; utilize non-replicative phagemids	[58,63,68,81]

7. Synergistic Integrations and Advanced Emerging Technologies

Combining CRISPR/Cas9 with complementary biotechnologies offers new avenues for improving delivery efficiency, reducing resistance, and enhancing therapeutic efficacy [4,91,95].

7.1. Nanotechnology-Enhanced Delivery Systems

Combining CRISPR constructs with inorganic or organic nanoparticles improves therapeutic delivery into challenging biological environments [4,75,91]. Encapsulating Cas9–sgRNA complexes within functionalized lipid nanoparticles or polymeric vectors protects the payload from enzymatic degradation, enhances cellular uptake, and improves penetration through thick bacterial biofilms [4,75,92]. Functionalizing nanoparticle surfaces with targeted ligands or antibodies allows for selective binding to specific bacterial surface antigens, minimizing non-target uptake [4,80,91].

7.2. Multiplexed Single-Guide RNA Strategies

Deploying single sgRNAs leaves therapeutic systems vulnerable to escape mutations [93,100]. Multiplexed CRISPR platforms address this limitation by expressing multiple sgRNAs simultaneously from a single transcript [93,94]. By targeting several distinct resistance genes or combining resistance target genes with essential chromosomal loci, multiplexed systems dramatically reduce the likelihood of bacterial escape, as acquiring simultaneous mutations across multiple target sites is extraordinarily rare [93,94,100].

7.3. Synthetic Biology and Live Probiotic Therapeutics

Integrating CRISPR/Cas9 into synthetic biology circuits enables the creation of intelligent, responsive live therapeutics [76,81]. Commensal bacteria can be engineered with inducible promoters that trigger the production and conjugative transfer of CRISPR platforms only in the presence of specific pathogen signals or inflammation markers [76,81]. Incorporating synthetic kill switches ensures that engineered probiotics self-destruct once their therapeutic objective is complete, providing strict biocontainment [76,81].

7.4. Combination Therapies with Antimicrobial Peptides (AMPs)

Co-administering CRISPR/Cas9 platforms with antimicrobial peptides (AMPs) creates a powerful multi-stage therapeutic effect [91,95]. AMPs permeabilize the bacterial outer and inner membranes, facilitating the entry of CRISPR delivery vectors (e.g., phagemids or nanoparticles) into the target cell [91,95]. Simultaneously, CRISPR-mediated plasmid curing or gene knockout restores sensitivity to co-administered traditional antibiotics or the AMPs themselves, resulting in synergistic antimicrobial activity [91,95,96].

8. Strategic Roadmap for Clinical and Translational Implementation

Transitioning CRISPR-based antimicrobials from preclinical research to routine clinical practice requires a systematic, phased implementation roadmap [46,89,97].

Target Identification & In Silico Optimization: Utilize high-throughput genomic sequencing and bioinformatic pipelines to select conserved, high-impact target sequences across pathogenic strains while screening for potential off-target matches in host human genomes [89,96].

• Delivery Vector Refinement: Optimize delivery vehicles—such as engineered phagemids with expanded host ranges or surface-functionalized nanoparticles—to ensure high-efficiency entry into target bacteria and effective biofilm penetration [36,75,80].
• Preclinical Safety & Efficacy Profiling: Conduct comprehensive in vivo evaluations using animal infection models to assess pharmacokinetic profiles, clearance rates, off-target impacts, and effects on host microbiome stability [46,89,97].
• GMP Manufacturing & Regulatory Approval: Develop scalable, standard manufacturing protocols under Good Manufacturing Practice (GMP) conditions and establish clear regulatory pathways with international agencies (e.g., FDA, EMA) for clinical-grade production and safety monitoring [46,70,89].

9. Conclusion

CRISPR/Cas9 technology represents a transformative frontier in the fight against bacterial antimicrobial resistance. By enabling precise, sequence-specific targeting of antibiotic resistance determinants, mobile genetic elements, and essential chromosomal genes, CRISPR platforms offer a powerful alternative to traditional broad-spectrum antibiotics. The ability to cure resistance plasmids, prevent horizontal gene transfer, disrupt biofilms, and re-sensitize MDR pathogens while preserving beneficial commensal microflora addresses key limitations of current antimicrobial strategies.

However, realizing the full translational potential of CRISPR/Cas9 antimicrobials requires addressing critical challenges, including delivery vector efficiency, bacterial anti-CRISPR defenses, off-target effects, and complex regulatory considerations. Continued interdisciplinary collaboration combining gene editing, nanotechnology, synthetic biology, and clinical microbiology will be essential to overcome these hurdles. With sustained innovation and careful safety evaluation, CRISPR/Cas9 platforms hold immense promise as next-generation precision antimicrobials to combat the global burden of drug-resistant bacterial infections.